

DON AGRO INTERNATIONAL LIMITED

Registration No. 201835258H

(Incorporated in the Republic of Singapore)

1) MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF NOVEMBER 2025; AND

2) UPDATE OF MILESTONES IN OBTAINING NEW BUSINESS

The Board of Directors (the “**Board**” or the “**Directors**”) of Don Agro International Limited (the “**Company**”) refers to the announcement released on the SGXNet on 8 July 2024 notifying shareholders of its cash company status pursuant to Rule 1017(1)(a) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (the “**Catalist Rules**”) and its previous announcement dated 28 November 2025 on the monthly updates.

Pursuant to Catalist Rule 1017(1)(b), the Board wishes to announce the following:

1. MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF NOVEMBER 2025

a) The Company’s assets and liabilities as at 30 November 2025 were as follows:

	<u>\$'000</u>
Assets	
Long-term investment	534
Trade and other receivables	45,541
Cash and cash equivalents	<u>25,304</u>
Total assets	<u>71,379</u>

	<u>\$'000</u>
Liabilities	
Trade and other payables	1,359
Current tax liabilities	89
Provisions	<u>39</u>
Total liabilities	<u>1,487</u>
Net assets	<u>69,892</u>

(b) The Company’s utilisation of cash from 1 November 2025 to 30 November 2025 was as follows:

	<u>RR'000¹ & 2</u>	<u>\$'000</u>
Opening cash and bank balances as at 1 November 2025	1,518,996	24,256
Add receipts:		
Interest income from deposit	15,597	253
Foreign currency translation adjustment	-	<u>1,242</u>
Total receipts	<u>15,597</u>	<u>1,495</u>
Less payments:		
Bank charges and miscellaneous	(105)	(2)
General and administrative expenses	(25,816)	<u>(445)</u>

¹ Relates to Russian subsidiaries of the Company and does not relate to the Company

² RR 62.09 to \$ 1 as at 1 November 2025; RR 61.57 to \$ 1 for November 2025; RR 59.72 to \$ 1 as at 30 November 2025.

Total payments	<u>(25,921)</u>	<u>(447)</u>
Closing cash and bank balances as at 30 November 2025	1,508,582	25,304

All figures set out in this announcement have not been reviewed or audited by the Company's auditors.

2. UPDATE OF MILESTONES IN OBTAINING A NEW BUSINESS

As mentioned in the announcement dated 12 September 2024 in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC (the “**Proposed Acquisition Announcement**”), that JSC Tetra, a wholly-owned subsidiary of the Company had, on 6 September 2024, entered into the agreements in respect of the proposed acquisition of 99.99% of the shares in 812 Capital LLC and 11.50% of the shares in Centre for Innovative Medical Technologies, LLC (together with their respective subsidiaries, the “**Target Group**”).

The Target Group is a Russian network of expert oncology clinics operating under the “Euroonco” brand that provide a full range of cancer diagnostics and treatment. Entities operating under the Euroonco brand, focus primarily on providing a full range of cancer diagnostics and treatment services, as well as all types of antitumor and palliative treatment. Euroonco has expert oncology clinics and information and service centres in Moscow, Saint Petersburg and Krasnodar. Please refer to the Proposed Acquisition Announcement for further details.

As announced on 21 January 2025, the Company had on 17 January 2025 received a letter from SGX-ST informing that SGX-ST has no objections to the, Cash Utilisation Waiver, Escrow Requirement Waiver and Continued Trading Application (the “**Waiver and Application Confirmation**”) (the “**Waiver Announcement**”) subject to the satisfaction of certain conditions (the “**Conditions**”). Please refer to the Waiver Announcement for further details.

As announced on 27 February 2025, the Group has fulfilled the Conditions as stated in the Waiver and Application Confirmation. For details, please refer to announcement dated 27 February 2025 for further details.

In March 2025, the Consideration Advance Payments and payment of the CIMT Stake Consideration (as defined in the Proposed Acquisition Announcement) of RR 2,220,000,000 for the proposed acquisition of medical business (equivalent to approximately S\$34,495,000)³ were remitted to the Vendors (as defined in the Proposed Acquisition Announcement) after obtaining the Waiver and Application Confirmation from SGX-ST on 17 January 2025 as mentioned above.

As announced on 1 June 2025, the Company received the letter from the SGX advising that SGX-ST has no objections to the Company's application for a waiver from the requirement to disclose the pro forma financial statements of the enlarged group (the “**Pro Forma Waiver Announcement**”). The waiver is subject to the satisfaction of certain conditions. Please refer to the Pro Forma Waiver Announcement for further details.

The Company's auditors and legal advisors are in the midst of conducting audit and due diligence for the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC. The Company is also in the midst of preparing a circular, which will be disseminated to the Company's shareholders in due course, in accordance with SGX-ST requirements before the extraordinary general meeting to be convened.

In May 2025 JSC Tetra extended a short-term loan amounted to RR 236,000,000 or approximately S\$3.8 million (“**Loan**”) to the Target Group in order to provide funding for an acquisition of groups of companies which operates polyclinic in Moscow under Uni Clinica brand (“**Uni Medica**”), acquisition of which allows

³ Based on the average exchange rate of S\$1.00 = RR 64.36 for March 2025

the Target Group to expand its medical facilities significantly. For avoidance of doubt, the Loan provided is not part of the Company's Escrowed Amount.

On 17 June 2025, the Company submitted an application to the Singapore Exchange Securities Trading Limited through PrimePartners Corporate Finance Pte. Ltd., for a six month extension for the Company to meet the requirements for a new listing pursuant to Rule 1017(2) of the Catalist Rules (the “**Extension Application**”). On 3 July 2025, the Company announced that the Company, had on 2 July 2025, received a letter from the SGX-ST advising that the SGX-ST has no objections to the Extension Application. For further details, please refer to the announcement dated 3 July 2025.

On 7 October 2025 the Group released an announcement announcing the entry into a loan agreement with LLC 812 Capital and CIMT to record and memorialise the formal terms and conditions of the Loan.

As announced on 12 November 2025 JSC Tetra entered into supplemental agreements to amend the terms of: (a) the Balance Stake Preliminary Agreement; (b) the CIMT Stake Preliminary Agreement; (c) the Minority Stake Agreement; and (d) the Options Agreements.

On 20 November 2025 the Group have submitted Notification to SGX-ST in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC by JSC Tetra being a very substantial acquisition under the Catalist Rules of SGX-ST marking a major milestone in the Group's journey to complete the Proposed Acquisitions.

There are no other updates of milestones in obtaining new business for November 2025 and Company is still in the midst of progressing Proposed Acquisitions.

BY ORDER OF THE BOARD

Marat Devlet-Kildeyev
Chief Executive Officer and Executive Director
30 December 2025

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.